ArticlePloS one2016
Optical Imaging of PARP1 in Response to Radiation in Oral Squamous Cell Carcinoma.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Emerging In Vivo Imaging Modalities for Improved Glioblastoma Surgery and Monitoring.Biomedicines · 2026Review
- Polyethylene Glycol 3350 (PEG 3350) as a Practical Vehicle for Rapid Reconstitution of PARPi-FL Formulations for Clinical Use.Molecular imaging and biology · 2023Article
- Pleiotropic role of PARP1: an overview.3 Biotech · 2022Review
- A phase I study of a PARP1-targeted topical fluorophore for the detection of oral cancer.European journal of nuclear medicine and molecular imaging · 2021Article
- PARP1: A Potential Molecular Marker to Identify Cancer During Colposcopy Procedures.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
- [Molecular imaging · 2021Article
- Fluorescence-guided resection of tumors in mouse models of oral cancer.Scientific reports · 2020Article
- Targeted Brain Tumor Radiotherapy Using an Auger Emitter.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Article
- Validation of the use of a fluorescent PARP1 inhibitor for the detection of oral, oropharyngeal and oesophageal epithelial cancers.Nature biomedical engineering · 2020Article
- Fluorescence Image-Guided Surgery - a Perspective on Contrast Agent Development.Proceedings of SPIE--the International Society for Optical Engineering · 2020Article
- CAF-1 Subunits Levels Suggest Combined Treatments with PARP-Inhibitors and Ionizing Radiation in Advanced HNSCC.Cancers · 2019Article
- PET Imaging of PARP Expression UsingJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Article
- Targeted PET imaging strategy to differentiate malignant from inflamed lymph nodes in diffuse large B-cell lymphoma.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Effects of low-dose radiation on adaptive response in colon cancer stem cells.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2017Article
- Molecular Imaging of PARP.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2017Review
- Current Practice and Emerging Molecular Imaging Technologies in Oral Cancer Screening.Molecular imagingArticle
- Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[Nuclear medicine and biologyArticle
- Preclinical and first-in-human-brain-cancer applications of [Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Targeting and inhibiting DNA repair pathways is a powerful strategy of controlling malignant growth. One such strategy includes the inhibition of PARP1, a central element in the intracellular DNA damage response. To determine and visualize the expression and intercellular distribution of PARP1 in vivo, and to monitor the pharmacokinetics of PARP1 targeted therapeutics, fluorescent small probes were developed. To date, however, it is unclear how these probes behave in a more realistic clinical setting, where DNA damage has been induced through one or more prior lines of therapy. Here, we use one such imaging agent, PARPi-FL, in tissues both with and without prior DNA damage, and investigate its value as a probe for PARP1 imaging. We show that PARP1 expression in oral cancer is high, and that the uptake of PARPi-FL is selective, irrespective of whether cells were exposed to irradiation or not. We also show that PARPi-FL uptake increases in response to DNA damage, and that this increase is reflected in higher enzyme expression. Our findings provide a framework for measuring exposure of cells to external beam radiation, and could help to elucidate the effects of such treatments non-invasively in mouse models of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.